Skip to main content
Top
Published in: BMC Gastroenterology 1/2020

Open Access 01-12-2020 | Research article

HFD and HFD-provoked hepatic hypoxia act as reciprocal causation for NAFLD via HIF-independent signaling

Authors: Xiaofang Zhang, Caoxin Huang, Xuejun Li, Zhaoshui Shangguan, Wenjing Wei, Suhuan Liu, Shuyu Yang, Yijie Liu

Published in: BMC Gastroenterology | Issue 1/2020

Login to get access

Abstract

Background

The occurrence of non-alcoholic fatty liver disease (NAFLD) is found to be higher in patients with obstructive sleep apnea (OSA), which is characterized by intermittent hypoxia. Activation of hypoxia-inducible factors has been shown in the development and progression of NAFLD, implying a cause and effects relationship between NAFLD and hypoxia. The present study was designed to investigate the interaction of lipotoxicity and hypoxia in the pathogenesis of NAFLD using mice model with high-fat diet (HFD) feeding or hypoxic treatment.

Methods

NAFLD model was induced in mice by HFD feeding, and in cultured primary hepatocytes by administration of palmitate acid. Mouse hypoxic model was produced by placing the mice in a Animal incubator with oxygen concentration at 75% followed by a 21% oxygen supplement. Hypoxic condition was mimicked by treating the hepatocytes with cobalt chloride (CoCl2) or 1% oxygen supply. Pimonidazole assay was conducted to evaluate hypoxia. Lipid metabolic genes were measured by real-time polymerase-chain reaction. HIF-1α and HIF-2α genes were silenced by siRNA.

Results

HFD feeding and palmitate acid treatment provoked severe hepatic hypoxia along with TG accumulation in mice and in cultured primary hepatocytes respectively. Conversely, hypoxia induced hepatic TG accumulation in mice and in cultured primary hepatocytes. Hypoxic treatment inhibited the expression of lipolytic genes, while increased the expression of lipogenicgenes in mice. Although both lipotoxicity and hypoxia could activate hepatic hypoxia-induced factor 1α and 2α, while neither lipotoxicity- nor hypoxia- induced hepatic steatosis was affected when HIF was knocked down.

Conclusions

HFD resulted in hepatic TG accumulation and concomitant hypoxia. Conversely, hypoxia induced hepatic TG accumulation in mice and in cultured heptocytes. Thus lipotoxicity and hypoxia might work as reciprocal causation and orchestrate to promote the development of NAFLD.
Literature
1.
go back to reference El-Kader SMA, Ashmawy ED. Non-alcoholic fatty liver disease: the diagnosis andmanagement. World J Hepatol. 2015;7(6):846–58.CrossRef El-Kader SMA, Ashmawy ED. Non-alcoholic fatty liver disease: the diagnosis andmanagement. World J Hepatol. 2015;7(6):846–58.CrossRef
2.
go back to reference Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9(16):715–32.CrossRef Benedict M, Zhang X. Non-alcoholic fatty liver disease: an expanded review. World J Hepatol. 2017;9(16):715–32.CrossRef
3.
go back to reference Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia. 2016;59(6):1141–4.CrossRef Byrne CD, Targher G. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia. 2016;59(6):1141–4.CrossRef
4.
go back to reference Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13(1):40.CrossRef Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13(1):40.CrossRef
5.
go back to reference Bruce KD, Cagampang FR. Epigenetic priming of the metabolic syndrome. Toxicol Methods. 2011;21(4):353–61.CrossRef Bruce KD, Cagampang FR. Epigenetic priming of the metabolic syndrome. Toxicol Methods. 2011;21(4):353–61.CrossRef
6.
go back to reference Cakmak E, Duksal F, Altinkaya E, Acibucu F, Dogan OT, Yonem O, et al. Association between the severity of nocturnal hypoxia in obstructive sleep apnea and non-alcoholic fatty liver damage. Hepatitis Mon. 2015;15(11):e32655. Cakmak E, Duksal F, Altinkaya E, Acibucu F, Dogan OT, Yonem O, et al. Association between the severity of nocturnal hypoxia in obstructive sleep apnea and non-alcoholic fatty liver damage. Hepatitis Mon. 2015;15(11):e32655.
7.
go back to reference Guilleminault C. Clinical features and evaluation of obstructive sleep apnea and upper airway resistance syndrome. In: Principles and practice of sleep medicine. 2005. p. 1043–52. Guilleminault C. Clinical features and evaluation of obstructive sleep apnea and upper airway resistance syndrome. In: Principles and practice of sleep medicine. 2005. p. 1043–52.
8.
go back to reference Siques P, Brito J, Leon-Velarde F, Barrios L, Cruz JJDL, Lopez V, et al. Hematological and lipid profile changes in sea-level natives after exposure to 3550-m altitude for 8 months. High Altit Med Biol. 2007;8(4):286–95.CrossRef Siques P, Brito J, Leon-Velarde F, Barrios L, Cruz JJDL, Lopez V, et al. Hematological and lipid profile changes in sea-level natives after exposure to 3550-m altitude for 8 months. High Altit Med Biol. 2007;8(4):286–95.CrossRef
9.
go back to reference Siques P, Brito J, Naveas N, Pulido R, De la Cruz JJ, Mamani M, et al. Plasma and liver lipid profiles in rats exposed to chronic hypobaric hypoxia: changes in metabolic pathways. High Alt Med Biol. 2014;15(3):388–95.CrossRef Siques P, Brito J, Naveas N, Pulido R, De la Cruz JJ, Mamani M, et al. Plasma and liver lipid profiles in rats exposed to chronic hypobaric hypoxia: changes in metabolic pathways. High Alt Med Biol. 2014;15(3):388–95.CrossRef
10.
go back to reference Aijuan Q, Matthew T, Xiang X, Tsutomu M, Daniel M, Pierre C, et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology. 2011;54(2):472–83.CrossRef Aijuan Q, Matthew T, Xiang X, Tsutomu M, Daniel M, Pierre C, et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology. 2011;54(2):472–83.CrossRef
11.
go back to reference Morello E, Sutti S, Foglia B, Novo E, Cannito S, Bocca C, et al. Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. Hepatology. 2017;67:2196–214.CrossRef Morello E, Sutti S, Foglia B, Novo E, Cannito S, Bocca C, et al. Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein. Hepatology. 2017;67:2196–214.CrossRef
12.
go back to reference Polotsky VY, Jianguo L, Punjabi NM, Rubin AE, Smith PL, Schwartz AR, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol. 2010;552(1):253–64.CrossRef Polotsky VY, Jianguo L, Punjabi NM, Rubin AE, Smith PL, Schwartz AR, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol. 2010;552(1):253–64.CrossRef
13.
go back to reference Bevans-Fonti S. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity. 2012;19(11):2167–74. Bevans-Fonti S. Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity. 2012;19(11):2167–74.
14.
go back to reference Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med. 2016;94(6):613–27.CrossRef Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med. 2016;94(6):613–27.CrossRef
15.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.CrossRef Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.CrossRef
16.
go back to reference Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metab Clin Exp. 2016;65(8):1124–35.CrossRef Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metab Clin Exp. 2016;65(8):1124–35.CrossRef
17.
go back to reference Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, et al. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm. 2015;2015:1–10.CrossRef Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, et al. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm. 2015;2015:1–10.CrossRef
18.
go back to reference Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res. 2005;97(7):698–706.CrossRef Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res. 2005;97(7):698–706.CrossRef
19.
go back to reference Mesarwi OA, Shin MK, Bevans-Fonti S, Schlesinger C, Shaw J, Polotsky VY. Hepatocyte hypoxia inducible factor-1 mediates the development of liver fibrosis in a mouse model of nonalcoholic fatty liver disease. PLoS ONE. 2016;11(12):e0168572.CrossRef Mesarwi OA, Shin MK, Bevans-Fonti S, Schlesinger C, Shaw J, Polotsky VY. Hepatocyte hypoxia inducible factor-1 mediates the development of liver fibrosis in a mouse model of nonalcoholic fatty liver disease. PLoS ONE. 2016;11(12):e0168572.CrossRef
20.
go back to reference Wonbaek Y, Kyung Hee N, Jae Hee A, Hee YJ, Ji A, et al. HIF-1α expression as a protective strategy of HepG2 cells against fatty acid-induced toxicity. J Cell Biochem. 2014;115(6):1147–58.CrossRef Wonbaek Y, Kyung Hee N, Jae Hee A, Hee YJ, Ji A, et al. HIF-1α expression as a protective strategy of HepG2 cells against fatty acid-induced toxicity. J Cell Biochem. 2014;115(6):1147–58.CrossRef
Metadata
Title
HFD and HFD-provoked hepatic hypoxia act as reciprocal causation for NAFLD via HIF-independent signaling
Authors
Xiaofang Zhang
Caoxin Huang
Xuejun Li
Zhaoshui Shangguan
Wenjing Wei
Suhuan Liu
Shuyu Yang
Yijie Liu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2020
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-020-01515-5

Other articles of this Issue 1/2020

BMC Gastroenterology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.